Floatz logo

cd19-ucart

B-Cell Acute Lymphoblastic Leukemia, Adult

The General Hospital of Western Theater CommandCell therapyPhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the B-Cell Acute Lymphoblastic Leukemia, Adult cohort.

Asset / SponsorPhaseRating
Blinatumomab
Memorial Sloan Kettering Cancer Center
Phase 2BB
cd22 car-transduced t cells
Zhejiang University
Phase 2BB
Fludarabine
The First Affiliated Hospital of Soochow University
Phase 1/2B
Venetoclax
Zhejiang University
Phase 2CCC
Pembrolizumab
University of California, San Diego
Phase 1/2CCC

View all 9 →

Same molecule, other indications

cd19-ucart is also rated in:

B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →